Journal Article
. 2016 Jun; 2016:8121985.
doi: 10.1155/2016/8121985.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Michal Lotem 1 Sharon Merims 1 Stephen Frank 1 Tamar Hamburger 1 Aviram Nissan 2 Luna Kadouri 1 Jonathan Cohen 1 Ravid Straussman 3 Galit Eisenberg 1 Shoshana Frankenburg 1 Einat Carmon 2 Bilal Alaiyan 2 Shlomo Shneibaum 4 Zeynep Ozge Ayyildiz 5 Murat Isbilen 5 Kerem Mert Senses 5 Ilan Ron 6 Hanna Steinberg 1 Yoav Smith 7 Eitan Shiloni 8 Ali Osmay Gure 5 Tamar Peretz 1 
  • PMID: 27294163
  •     51 References
  •     11 citations


Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease recurrence. Patients and Methods. 126 patients received eight doses of irradiated autologous melanoma cells conjugated to dinitrophenyl and mixed with BCG. Delayed type hypersensitivity (DTH) response to unmodified melanoma cells was determined on the vaccine days 5 and 8. Gene expression analysis was performed on 35 tumors from patients with good or poor survival. Results. Median overall survival was 88 months with a 5-year survival of 54%. Patients attaining a strong DTH response had a significantly better (p = 0.0001) 5-year overall survival of 75% compared with 44% in patients without a strong response. Gene expression array linked a 50-gene signature to prognosis, including a cluster of four cancer testis antigens: CTAG2 (NY-ESO-2), MAGEA1, SSX1, and SSX4. Thirty-five patients, who received an autologous vaccine, followed by ipilimumab for progressive disease, had a significantly improved 3-year survival of 46% compared with 19% in nonvaccinated patients treated with ipilimumab alone (p = 0.007). Conclusion. Improved survival in patients attaining a strong DTH and increased response rate with subsequent ipilimumab suggests that the autologous vaccine confers protective immunity.

Defining the critical hurdles in cancer immunotherapy.
Bernard A Fox, Dolores J Schendel, +102 authors, Mary L Disis.
J Transl Med, 2011 Dec 16; 9. PMID: 22168571    Free PMC article.
The role of neoantigens in response to immune checkpoint blockade.
Nadeem Riaz, Luc Morris, +3 authors, Timothy A Chan.
Int Immunol, 2016 Apr 07; 28(8). PMID: 27048318    Free PMC article.
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Craig L Slingluff, Gina R Petroni, +11 authors, Patrice K Rehm.
J Clin Oncol, 2008 Sep 24; 26(30). PMID: 18809608    Free PMC article.
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Vincenzo Russo, Lorenzo Pilla, +27 authors, Marco Bregni.
Int J Cancer, 2012 Nov 16; 132(11). PMID: 23151995
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.
Sven Brode, Anne Cooke.
Crit Rev Immunol, 2008 Jun 11; 28(2). PMID: 18540827
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
Ute E Burkhardt, Ursula Hainz, +28 authors, Catherine J Wu.
J Clin Invest, 2013 Aug 06; 123(9). PMID: 23912587    Free PMC article.
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
David Berd, Takami Sato, +2 authors, Michael J Mastrangelo.
J Clin Oncol, 2003 Dec 24; 22(3). PMID: 14691123
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
J M Kirkwood, J G Ibrahim, +7 authors, R H Blum.
J Clin Oncol, 2000 Jun 16; 18(12). PMID: 10856105
Highly Cited.
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
Steven A Rosenberg, Richard M Sherry, +14 authors, Seth M Steinberg.
J Immunol, 2005 Oct 21; 175(9). PMID: 16237114
Highly Cited.
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Alexander M M Eggermont, Stefan Suciu, +13 authors, EORTC Melanoma Group.
Lancet, 2005 Oct 04; 366(9492). PMID: 16198768
Cancer immunotherapy: moving beyond current vaccines.
Steven A Rosenberg, James C Yang, Nicholas P Restifo.
Nat Med, 2004 Sep 02; 10(9). PMID: 15340416    Free PMC article.
Highly Cited.
Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.
D L Morton, L J Foshag, +7 authors, R Elashoff.
Ann Surg, 1992 Oct 01; 216(4). PMID: 1417196    Free PMC article.
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
Takashi Miyatake, Yutaka Ueda, +12 authors, Tadashi Kimura.
J Cancer Res Clin Oncol, 2012 Nov 20; 139(3). PMID: 23160854
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
I Jolanda M de Vries, Monique R Bernsen, +7 authors, Gosse J Adema.
J Clin Oncol, 2005 Aug 20; 23(24). PMID: 16110035
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
A Escobar, M López, +9 authors, F Salazar-Onfray.
Clin Exp Immunol, 2005 Nov 22; 142(3). PMID: 16297169    Free PMC article.
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.
N Cascinelli, F Belli, +3 authors, A Morabito.
Lancet, 2001 Sep 25; 358(9285). PMID: 11567700
Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Michal Lotem, Arthur Machlenkin, +9 authors, Tamar Peretz.
Clin Cancer Res, 2009 Jul 16; 15(15). PMID: 19602547
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
John M Kirkwood, Judith Manola, +4 authors, Eastern Cooperative Oncology Group.
Clin Cancer Res, 2004 Mar 12; 10(5). PMID: 15014018
Highly Cited.
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Paul F Robbins, Yong-Chen Lu, +9 authors, Steven A Rosenberg.
Nat Med, 2013 May 07; 19(6). PMID: 23644516    Free PMC article.
Highly Cited.
T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress.
Paulo C Rodríguez, Augusto C Ochoa.
Semin Cancer Biol, 2005 Nov 22; 16(1). PMID: 16298138
Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
Ji-Yan Liu, Yang Wu, +9 authors, Yi-Xin Zeng.
Cancer Immunol Immunother, 2007 Apr 19; 56(10). PMID: 17440723
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
Y T Chen, M J Scanlan, +7 authors, L J Old.
Proc Natl Acad Sci U S A, 1997 Mar 04; 94(5). PMID: 9050879    Free PMC article.
Highly Cited.
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Jianda Yuan, Matthew Adamow, +16 authors, Sacha Gnjatic.
Proc Natl Acad Sci U S A, 2011 Sep 22; 108(40). PMID: 21933959    Free PMC article.
Highly Cited.
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Eddy C Hsueh, Estela Famatiga, +2 authors, Donald L Morton.
Ann Surg Oncol, 2004 Sep 24; 11(10). PMID: 15383418
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
A Baars, A M Claessen, +9 authors, H M Pinedo.
Ann Oncol, 2000 Oct 19; 11(8). PMID: 11038032
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
B W Hancock, K Wheatley, +9 authors, M Gore.
J Clin Oncol, 2003 Dec 11; 22(1). PMID: 14665609
A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas.
Rongyi Chen, Guoxue Zhang, +2 authors, Jiaxi Lin.
Diagn Pathol, 2014 Aug 15; 9. PMID: 25116415    Free PMC article.
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Alexander M M Eggermont, Stefan Suciu, +14 authors, Alan Spatz.
J Clin Oncol, 2013 Sep 11; 31(30). PMID: 24019551
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
Satoshi Wada, Christopher M Jackson, +10 authors, Charles G Drake.
J Transl Med, 2013 Apr 06; 11. PMID: 23557194    Free PMC article.
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.
Marilisa Carsana, Gabrina Tragni, +7 authors, Maria Luisa Sensi.
Cancer Gene Ther, 2002 Mar 16; 9(3). PMID: 11896440
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
François Ghiringhelli, Nicolas Larmonier, +7 authors, François Martin.
Eur J Immunol, 2004 Feb 10; 34(2). PMID: 14768038
Highly Cited.
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Sofie Wilgenhof, An M T Van Nuffel, +10 authors, Bart Neyns.
J Immunother, 2011 May 18; 34(5). PMID: 21577140
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J Schwartzentruber, David H Lawson, +23 authors, Patrick Hwu.
N Engl J Med, 2011 Jun 03; 364(22). PMID: 21631324    Free PMC article.
Highly Cited.
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Alexander M M Eggermont, Stefan Suciu, +12 authors, Alan Spatz.
Eur J Cancer, 2011 Nov 08; 48(2). PMID: 22056637
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Wim H J Kruit, Stefan Suciu, +14 authors, Ulrich Keilholz.
J Clin Oncol, 2013 May 30; 31(19). PMID: 23715572
Highly Cited.
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
M Lotem, T Peretz, +8 authors, E Shiloni.
Br J Cancer, 2002 Jun 27; 86(10). PMID: 12085200    Free PMC article.
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Paul Sabbatini, Takemasa Tsuji, +18 authors, Sacha Gnjatic.
Clin Cancer Res, 2012 Oct 04; 18(23). PMID: 23032745
Highly Cited.
Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
Yoshihiro Muragaki, Takashi Maruyama, +16 authors, Tomokatsu Hori.
J Neurosurg, 2011 May 17; 115(2). PMID: 21568657
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Ninke Leffers, Annechien J A Lambeck, +17 authors, Hans W Nijman.
Int J Cancer, 2009 Jul 22; 125(9). PMID: 19621448
Intrathymic selection: new insight into tumor immunology.
Dmitry B Kazansky.
Adv Exp Med Biol, 2007 Aug 24; 601. PMID: 17713000
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J M Kirkwood, M H Strawderman, +3 authors, R H Blum.
J Clin Oncol, 1996 Jan 01; 14(1). PMID: 8558223
Highly Cited.
Requirements for induction of T cell tolerance to DNFB: efficiency of membrane-associated DNFB.
H N Claman, S D Miller.
J Immunol, 1976 Aug 01; 117(2). PMID: 1084899
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.
Ali O Gure, Ramon Chua, +8 authors, Nasser K Altorki.
Clin Cancer Res, 2005 Nov 22; 11(22). PMID: 16299236
Highly Cited.
Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination.
Martin O C Ota, Johan Vekemans, +10 authors, Arnaud Marchant.
J Immunol, 2002 Jan 05; 168(2). PMID: 11777990
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).
Carsten Schaefer, Lisa H Butterfield, +5 authors, Theresa L Whiteside.
Int J Cancer, 2011 Oct 25; 131(4). PMID: 22021080    Free PMC article.
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
M E Christine Lutsiak, Roshanak T Semnani, +3 authors, Helen Sabzevari.
Blood, 2004 Dec 14; 105(7). PMID: 15591121
Highly Cited.
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Simone Mocellin, Marko B Lens, +2 authors, Vanna Chiarion Sileni.
Cochrane Database Syst Rev, 2013 Jun 19; (6). PMID: 23775773
Systematic Review.
Immunologic correlates of the abscopal effect in a patient with melanoma.
Michael A Postow, Margaret K Callahan, +18 authors, Jedd D Wolchok.
N Engl J Med, 2012 Mar 09; 366(10). PMID: 22397654    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Future approaches in immunotherapy.
Brian Rini.
Semin Oncol, 2014 Dec 03; 41 Suppl 5. PMID: 25438998
Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study.
José Mordoh, María Betina Pampena, +11 authors, María Marcela Barrio.
Front Immunol, 2017 Jun 18; 8. PMID: 28620382    Free PMC article.
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.
Kerem M Senses, Mehdi Ghasemi, +7 authors, Ali O Gure.
Medchemcomm, 2017 Jul 04; 8(1). PMID: 28670440    Free PMC article.
Targeting Toll-Like Receptors for Cancer Therapy.
Marc J Braunstein, John Kucharczyk, Sylvia Adams.
Target Oncol, 2018 Sep 20; 13(5). PMID: 30229471
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
Sruthi Ravindranathan, Khue G Nguyen, +5 authors, David A Zaharoff.
Breast Cancer Res, 2018 Oct 24; 20(1). PMID: 30348199    Free PMC article.
Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis.
Jinwei Liu, Zhaojin Yu, +3 authors, Hua Gao.
Oncol Lett, 2019 Oct 16; 18(5). PMID: 31611988    Free PMC article.
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.
Baris Kucukkaraduman, Can Turk, +7 authors, Ali O Gure.
ACS Med Chem Lett, 2020 May 22; 11(5). PMID: 32435407    Free PMC article.
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Enrique Podaza, Ibel Carri, +9 authors, María Marcela Barrio.
Front Immunol, 2020 Jun 26; 11. PMID: 32582212    Free PMC article.
Identification of biomarkers for early diagnosis of Parkinson's disease by multi-omics joint analysis.
Chaokai Hu, Cherng Jyh Ke, Chungyu Wu.
Saudi J Biol Sci, 2020 Jul 28; 27(8). PMID: 32714032    Free PMC article.
Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers.
Estela Noguera-Ortega, Sandra Guallar-Garrido, Esther Julián.
Cancers (Basel), 2020 Jul 09; 12(7). PMID: 32635668    Free PMC article.
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness.
Asunción Espinosa-Sánchez, Elisa Suárez-Martínez, Laura Sánchez-Díaz, Amancio Carnero.
Front Oncol, 2020 Sep 29; 10. PMID: 32984007    Free PMC article.
Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
So-Woon Kim, Young Il Kim, +8 authors, In Ja Park.
Mod Pathol, 2020 Jul 28; 34(1). PMID: 32709987